EORTC abstracts accepted for presentation at the 2012 ASCO Annual Meeting

Oral Presentations

EORTC Gastrointestinal Tract Cancer Group

Abstract ID: 3508

EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme John Poston, Peter M. Schlag, Philippe Rougier, Wolf Bechstein, John Neil Primrose, Euan Thomas Walpole, Murielle E. Mauer, Thomas Gruenberger.

EORTC Quality of Life Group

Abstract ID: 6002

An international study of multi-trial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites. Chantal Quinten, Efstathios Zikos, Miriam Sprangers, Eva Greimel, Francesca Martinelli, Bryce B. Reeve, Jolie Ringash, Carolyn Gotay, John T Maringwa, Corneel Coens, Divine Ewane Ediebah, Madeleine King, David Osoba, Charles S. Cleeland, Henning Flechtner, Jospeh Schmucker-Von Koch, Martin J. B. Taphoorn, Joachim Weis, Kristin Bjordal, Andrew Bottomley.

EORTC Gynecological cancer Group

Abstract ID: LBA5000

Randomised phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. A GCIG and EORTC-GCG study. Ignace B. Vergote, Florence Joly, Dionyssios Katsaros, Corneel Coens, Alexander Reinthaller, Marcia Hall, Christopher B. Steer, Nicoletta Colombo, Anne Lesoin, Antonio Casado, Edgar Petru, John Green, Martin Buck, Isabelle Laure Ray-Coquard, Annamaria Ferrero, Laure Favier, Nicholas Reed, Herve Curve, Antonio Jimeno, Eric Pujade-Lauraine

EORTC Brain Tumor Group

Abstract ID: 91655

Long term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). Martin J. Van Den Bent, Khê Hoang-Xuan, Alba Ariela Brandes, Johan M Kros, Mathilde C.M. Kouwenhoven, Martin J. B. Taphoorn, Jean-Yves Delattre, Hans J.J.B. Bernsen, Marc Frenay, Cees Tijssen, Wolfgang Grisold, Laszlo Sipos, Roelien H. Enting, Winand N.M. Dinjens, Pim French, Charles J Vecht, Anouk Allgeier, Denis A. Lacombe, Thierry Gorlia.

EORTC Lymphoma Group

Abstract ID: 8002

ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in Stage III – IV high risk Hodgkin Lymphoma (HL): First Results of EORTC 20012 Intergroup Randomized Phase III Clinical Trial. P. Carde, M. Karrasch, C. Fortpied, P. Brice, H. Khaled, D. Caillot, I. Gaillard, S. Bologna, C. Ferme, P. Lugtenburg,
F. Morschhauser, I. Aurer, B. Coiffier, R. Meyer, M. Seftel, M. Wolf, B. Glimelius, A. Sureda, N. Mounier.

General Poster Sessions

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID: 10096

Analysis of the quality of reporting surgical procedures in patients undergoing resection for primary gastro-intestinal stromal tumors. a reporting tool derived from the EORTC–STBSG 62024 trial. Peter Hohenberger, Piotr Rutkowski, Sylvie Bonvalot, Frits van Coevorden, Eberhard Stoeckle, Christine Olungu, Monia Ouali, Paolo Giovanni Casali, Alessandro Gronchi

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID: 10067

Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS); Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo. Sandrine Marreaud, Winette T.A. Van der Graaf, Jean-Yves Blay, Sant P. Chawla, Jeeyun Lee, Binh Bui Nguyen, Paolo Giovanni Casali, Massimo Aglietta, Arthur P. Staddon, Yasuo Beppu, Axel Le Cesne, Hans Gelderblom, Ian Robert Judson, Nobuhito Araki, Monia Ouali, Mohamedraza Dewji, Alex Powell, George D. Demetri, Peter Hohenberger.

EORTC Headquarters

Abstract ID: 10602

The components of progression as explanatory variables for overall survival in the RECIST database. Saskia Litière, Elisabeth De Vries, Lesley Seymour, Daniel J. Sargent, Lalitha Shankar, Jan Bogaerts.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID: 4053

International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer. Franck Bonnetain, Adelaide Doussau, Simone Mathoulin-Pelissier, Bert A Bonsing, Bengt Glimelius, Karin Haustermans, Thierry Conroy, Jean-Luc Van Laethem, Roberto Labianca, Teresa Macarulla, Murielle E. Mauer, Manfred P. Lutz, Josep Tabernero, Aimery De Gramont, Pascal Hammel, Daniela Ellen Aust, Michel Ducreux, Julien Taïeb, John P. Neoptolemos, Laurence Collette.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID: TPS4140

Lapatinib in combination with ECF/x in EGFR1 positive first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071). Markus Hermann Moehler, Arno Schad, Murielle E. Mauer, Michel Praet, Francisco J. Sapunar, Kathryn Jane Briggs, Manfred P. Lutz, Arnaud Roth.

EORTC Quality of Life Group

Abstract ID: 6090

Health-related quality of life assessment in EORTC cancer clinical trials. Efstathios Zikos, Corneel Coens, Divine Ewane Ediebah, Chantal Quinten, Eva Greimel, Henning Flechtner, Martin J. B. Taphoorn, Jaap Reijneveld, Michael Koller, Andrew Bottomley.

EORTC Quality of Life Group

Abstract ID: 7607

Does change in health-related quality of life (HRQoL) score predict survival? analysis of a lung cancer RCT. Divine Ewane Ediebah, Corneel Coens, Efstathios Zikos, Chantal Quinten, Jolie Ringash, Carolyn Gotay, Elfriede Greimel, John T Maringwa, Madeleine King, Henning Flechtner, Martin J. B. Taphoorn, Jospeh Schmucker-Von Koch, Joachim Weis, Bryce B. Reeve, Egbert F Smit, Andrew Bottomley.

EORTC Lung Cancer Group

Abstract ID: 08052

Phase II study of Bortezomib (VELCADE) with cisplatin as first line treatment of malignant pleural mesothelioma (MPM) EORTC 08052. Mary ER O’Brien, Rabab M Gaafar, Sanjay Popat, Francesco Grossi, Allan Price, Dennis Talbot, Tania Cufer, Christain Ottensmeier, Sarah Danson, Athanasios Pallis, Baktiar Hasan, Jan Van Meerbeeck, Paul Baas.

EORTC Cutaneous Lymphoma Task Force

Abstract ID: 8076

Efficacy and safety of Bexarotene combined with Psoralen/Ultraviolet A Light (PUVA) compared to PUVA treatment alone in Stage IB-IIA Mycosis Fungoides (MF): Final Results from EORTC Cutaneous Lymphoma Task Force (CLTF) 21011. Sean Whittaker, Pablo Ortiz, Reinhard Dummer, Annamari Ranki, Baktiar Hasan, Bart Meulemans, Sylke Gellrich, Robert Knobler, Rudolf Stadler, Matthias Karrasch.

Poster Discussion Sessions

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID: 10009

PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. Winette T.A. Van Der Graaf, Jean-Yves Blay, Sant P. Chawla, Dong-Wan Kim, Binh Bui Nguyen, Paolo Giovanni Casali, Patrick Schoffski, Massimo Aglietta, Arthur P. Staddon, Yasuo Beppu, Axel Le Cesne, Hans Gelderblom, Ian Robert Judson, Nobuhito Araki, Monia Ouali, Sandrine Marreaud, Rachel Hodge, Mohamedraza Dewji, Angelo Paolo Dei Tos, Peter Hohenberger

EORTC Breast Cancer Group

Abstract ID: 1022

Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. Giuseppe Viale, Leen Slaets, Femke De Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

EORTC Melanoma Group

Abstract ID: 8532

Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. Serge Leyvraz, Stefan Suciu, Sophie Piperno-Neumann, Jean-Francois Baurain, Marcin Zdzienicki, Alessandro Testori, Ernie Marshall, Max E. Scheulen, Thomas Jouary, Sylvie Negrier, Jan Baptist Vermorken, Eckhart Kaempgen, Xavier Durando, Dirk Schadendorf, Ravichandra Karra Gurunath, Larissa Polders, Gaetan De Schaetzen, Simon Vanderschaeghe, Marie-Pierre Gauthier, Ulrich Keilholz.

Jennifer Crespo, Stéphanie Vandergooten and John Bean